JP2007297414A - 標的された部位特異的薬物送達組成物およびその使用 - Google Patents

標的された部位特異的薬物送達組成物およびその使用 Download PDF

Info

Publication number
JP2007297414A
JP2007297414A JP2007215329A JP2007215329A JP2007297414A JP 2007297414 A JP2007297414 A JP 2007297414A JP 2007215329 A JP2007215329 A JP 2007215329A JP 2007215329 A JP2007215329 A JP 2007215329A JP 2007297414 A JP2007297414 A JP 2007297414A
Authority
JP
Japan
Prior art keywords
microbubbles
albumin
odn
site
ultrasound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007215329A
Other languages
English (en)
Japanese (ja)
Inventor
Thomas R Porter
アール. ポーター トーマス
Patrick L Iversen
エル. イバーセン パトリック
Gary D Meyer
ディー. メイヤー ゲリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska System
Original Assignee
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska System filed Critical University of Nebraska System
Publication of JP2007297414A publication Critical patent/JP2007297414A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007215329A 1996-03-12 2007-08-21 標的された部位特異的薬物送達組成物およびその使用 Withdrawn JP2007297414A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61549596A 1996-03-12 1996-03-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP53279697A Division JP4774135B2 (ja) 1996-03-12 1997-03-12 標的された部位特異的薬物送達組成物およびその使用

Publications (1)

Publication Number Publication Date
JP2007297414A true JP2007297414A (ja) 2007-11-15

Family

ID=24465630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007215329A Withdrawn JP2007297414A (ja) 1996-03-12 2007-08-21 標的された部位特異的薬物送達組成物およびその使用

Country Status (7)

Country Link
EP (1) EP0888054B1 (de)
JP (1) JP2007297414A (de)
AT (1) ATE248511T1 (de)
AU (1) AU725693B2 (de)
CA (1) CA2248158A1 (de)
DE (1) DE69724599T2 (de)
WO (1) WO1997033474A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
EP0991427A2 (de) * 1996-10-28 2000-04-12 Marsden, John Christopher Verbesserungen an oder in verbindung mit diagnostischen/therapeutischen mitteln
AU733495B2 (en) 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1998018501A2 (en) * 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
CA2337361C (en) * 1998-07-13 2010-11-16 The Board Of Regents Of The University Of Nebraska Targeted site specific drug delivery compositions and method of use
GB9917416D0 (de) * 1999-07-23 1999-09-22 Univ Ulster
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
DE10108798A1 (de) * 2001-02-19 2002-09-26 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur ultraschallgestützten transmembranen Medikamentenapplikation in vivo
JPWO2003043663A1 (ja) * 2001-11-22 2005-03-10 アンジェスMg株式会社 臓器移植における拒絶反応を抑制する組成物およびその使用方法
WO2003080123A1 (fr) * 2002-03-22 2003-10-02 Anges Mg, Inc. Compositions delivrant un medicament biologiquement actif, et procede d'utilisation
US8012118B2 (en) 2006-03-08 2011-09-06 Fresenius Medical Care Holdings, Inc. Artificial kidney dialysis system
US8715221B2 (en) 2006-03-08 2014-05-06 Fresenius Medical Care Holdings, Inc. Wearable kidney
CA2661221C (en) 2006-08-24 2014-03-18 Fresenius Medical Care Holdings, Inc. Device for removing fluid from blood in a patient
US8454937B2 (en) 2006-09-12 2013-06-04 Temple University—Of The Commonwealth System of High Education Method and composition for the site-selective delivery using viruses encapsulated in microbubbles
AU2009320025B2 (en) 2008-11-03 2013-02-28 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis system
US20130072854A1 (en) * 2011-09-19 2013-03-21 General Electric Company Microbubble complexes and methods of use
WO2014117232A1 (pt) * 2013-02-04 2014-08-07 Farret Neto Abdo Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068334C (en) * 1990-10-05 1996-09-03 Bracco International B.V. Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
EP0732106A3 (de) * 1991-03-22 2003-04-09 Katsuro Tachibana Mikrobläschen enthaltende Verstärker zur Ultraschalltherapie von Erkrankungen
US5648098A (en) * 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
JP2001502349A (ja) * 1996-10-21 2001-02-20 ニユコメド・イメージング・アクシエセルカペト 造影剤におけるまたはこれに関する改良

Also Published As

Publication number Publication date
EP0888054A1 (de) 1999-01-07
AU2207197A (en) 1997-10-01
AU725693B2 (en) 2000-10-19
EP0888054B1 (de) 2003-09-03
ATE248511T1 (de) 2003-09-15
CA2248158A1 (en) 1997-09-18
WO1997033474A1 (en) 1997-09-18
DE69724599T2 (de) 2004-08-05
DE69724599D1 (de) 2003-10-09
EP0888054A4 (de) 1999-04-28

Similar Documents

Publication Publication Date Title
JP2007297414A (ja) 標的された部位特異的薬物送達組成物およびその使用
US5849727A (en) Compositions and methods for altering the biodistribution of biological agents
US6245747B1 (en) Targeted site specific antisense oligodeoxynucleotide delivery method
JP5049958B2 (ja) 超音波媒介デリバリー用ガス充填マイクロカプセル含有医薬組成物
Porter et al. Interaction of diagnostic ultrasound with synthetic oligonucleotide‐labeled perfluorocarbon‐exposed sonicated dextrose albumin microbubbles.
EP1046394A2 (de) Neue Zusammensetzungen zur Verwendung bei der Verabreichung von Verbindungen in das Zellinnere
CA2337361C (en) Targeted site specific drug delivery compositions and method of use
JP2001503407A (ja) 改良された診断/治療用薬剤
JP2001511765A (ja) 改良された診断/治療用薬剤
AU2012311659A1 (en) Microbubble complexes and methods of use
JP4774135B2 (ja) 標的された部位特異的薬物送達組成物およびその使用
KR100649035B1 (ko) 표적화된 부위특이적 약물 송달 조성물 및 사용방법
JP2001502719A (ja) 改良された診断/治療用薬剤
AU7825001A (en) Methods for delivering compounds into a cell
HK1251462B (zh) 微泡复合物及使用方法
HK1200362B (en) Microbubble complexes and methods of use
HRP970328A2 (en) Methods for delivering compounds into a cell

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110118

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110520